Delaying emergence of resistance to KRAS inhibitors with adaptive therapy: “treatment-to-contain” instead of “treatment-to-cure”

Por Hamdi, Amir Imran Faisal, Stanslas, Johnson
Publicado em 2022

Adaptive therapy to circumvent drug resistance to tyrosine kinase inhibitors in cancer: is it clinically relevant?

Por Hamdi, Amir Imran Faisal, Soon, Hin How, Islam, Mohammad Kaisarul, Chee, Jonathan Woei Lim, Stanslas, Johnson
Publicado em 2022